PLP-gp100

PLP-gp100 is a nanoparticle-based cancer vaccine candidate developed using the Protein-Like Polymer (PLP) platform. It consists of a polymeric backbone synthesized via ring-opening metathesis polymerization (ROMP), to which gp100 peptide antigens are conjugated via intracellularly cleavable disulfide linkages. The platform is designed to mimic the globular structure of native proteins, providing resistance to proteolysis and improved delivery to antigen-presenting cells (APCs). In preclinical melanoma models, PLP-gp100 has demonstrated the ability to elicit potent antigen-specific T-cell responses and reduce tumor burden, particularly when co-delivered with STING agonists like 2'3' cGAMP through electrostatic coupling.

Other names

Protein-Like Polymer-gp100gp100-PLPgp-100-PLPgp 100-PLP